Sprint Bioscience Q1 2023: VADA deal needed

Research Update

2023-05-11

06:45

Redeye provides its comment on Sprint Bioscience’s Q1 2023 report, and we judge that the company needs to close a VADA deal in the near future to strengthen its financial position.

Christian Binder

Ethel Luvall

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.